Initiative integrates Aranscia’s 2bPrecise and Spesana platforms with leading molecular laboratories to streamline genomic testing across Northside’s cancer care network
HOUSTON and ATLANTA, Sept. 22, 2026 /PRNewswire/ — Aranscia today announced a new initiative with Northside Hospital Cancer Institute designed to advance precision medicine and improve the integration of molecular diagnostic testing throughout its health system. Through the collaboration with Northside, Aranscia and its network of 12 leading molecular laboratories are creating a more connected molecular diagnostic ecosystem designed to make genomic testing easier to order, results easier to access, and clinically relevant information more actionable for physicians and care teams.
Historically, disparate laboratories have operated through different ordering processes, reporting formats, and technology platforms. This fragmentation can create challenges for clinicians and care teams seeking to efficiently order testing, track results, and incorporate molecular findings into treatment decisions.
Through this integration, Aranscia’s platform of software solutions, including 2bPrecise and Spesana, will enhance Northside Hospital Cancer Institute’s existing clinical, operational and analytical workflows with unified molecular diagnostic reports and discrete genomic data directly within Northside’s Oracle Health system. This functionality will help clinicians more efficiently incorporate diagnostic information into coordinated, patient-centered care. Northside clinicians will also benefit from the translation of complex genetic data into actionable insights that can guide treatment planning, help identify therapy opportunities, and support long-term patient care.
“This initiative represents an important step in our continued efforts to bring precision medicine into the everyday clinical workflow,” said Amy Boren, Director of Oncology Services at Northside Hospital. “By connecting our clinicians with a broader molecular laboratory ecosystem, we can help make genomic testing more accessible, more coordinated, and more actionable. Most importantly, this work is about ensuring that patients and their care teams can derive the greatest possible value from the increasingly important role of molecular diagnostics in cancer care.”
Beyond the immediate benefits, this integration also provides Northside with a foundation for continued innovation in precision oncology and genomic medicine. As the volume and complexity of molecular testing continues to grow, the ability to efficiently manage, organize, and utilize genomic information will become increasingly important to delivering high-quality care.
“Northside Hospital Cancer Institute has built a reputation for delivering exceptional cancer care to those directly within its communities,” said Carla Balch, Executive Director, Software & Products at Aranscia. “We are honored to support their continued leadership in precision medicine and their commitment to improving access and outcomes for all patients, directly within clinical EHR workflows.”
About Northside Hospital
Northside Hospital is Georgia’s leading healthcare system, serving patients at five acute-care hospitals in Atlanta, Canton, Cumming, Duluth and Lawrenceville and nearly 500 outpatient locations across the state. Northside is nationally recognized for world-class patient care, innovation and clinical excellence. The system leads the U.S. in newborn deliveries and stands among the state’s top providers of cancer care, cardiovascular, sports medicine, neuroscience, robotics and surgical services. Learn more at northside.com.
About Aranscia
Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more, visit www.aranscia.com.
About 2bPrecise
2bPrecise, an Aranscia company, is a suite of diagnostic and precision medicine technologies that enable transformative solutions at the point of care. 2bPrecise efficiently routes genetic and genomic data from molecular labs and clinical data sets, synthesizing them into a single clinical-genomic workflow. Precision medicine insights are incorporated into a clinician’s EHR workflow for immediate and timely use, with specialty application for oncology, pharmacogenomics, hereditary screening, and more. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for a range of genomic workflows including population analytics, clinical intervention programs, and research. For more information on 2bPrecise, please visit www.2bPrecise.com.
About Spesana
Spesana, an Aranscia company, has developed a universal healthcare platform to increase the velocity of patient access to the right care through improving clinical, financial, and operational workflows. Founded in 2019 by an experienced team of electronic medical record pioneers, Spesana’s framework for purpose driven healthcare interoperability incorporates a provider-centric approach to building solutions for challenges such as patient navigation, referral management, prior authorization, lab routing, and multi-site clinical collaboration. For more information on Spesana, please visit www.spesana.com.
Media Contact
Karina Stabile
Aria Marketing for Aranscia
(516) 317-5835
423093@email4pr.com
Katherine Watson
Northside Hospital
(404) 303-3405
423093@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aranscia-announces-molecular-laboratory-integration-initiative-with-northside-hospital-to-advance-precision-oncology-302886067.html
SOURCE Aranscia
